Table 4.
Significant related variables to second dose COVID-19 vaccine humoral response in a univariate analysis.
| Non-Responders n (%) | Low Responders n (%) | Responders n (%) | p (Ẋ2) | |
|---|---|---|---|---|
| ESID registry classification | 0.005 | |||
| CID | 1/1 (100) | 0 | 0 | |
| CVID | 5/14 (35.7) | 7/14 (50) | 2/14 (14.3) | |
| SID | 0 | 0 | 3/3 (100) | |
| TI | 1/1 (100) | 0 | 0 | |
| UnPAD | 0 | 4/11 (36.4) | 7/11 (63.6) | |
| Type of Ig defciency | 0.02 | |||
| IgG | 0/6 | 1/6 (16.7) | 5/6 (83.3) | |
| IgG + IgM | 0/4 | 1/4 (25) | 3/4 (75) | |
| IgG + IgA | 0/4 | 2/4 (50) | 2/4 (50) | |
| IgG + IgA + IgM | 7/16 (43.8) | 7/16 (43.8) | 2/16 (12.5) | |
| GLILD | 0.004 | |||
| YES | 3/3 (100) | 0 | 0 | |
| NO | 12/27 (44.4) | 11/27 (40.7%) | 4/27 (14.8) | |
| Immunosuppressive drugs < 3 months | 0.05 | |||
| YES | 3/5 (60) | 0 | 2/5 (40) | |
| NO | 4/25 (16) | 11/25 (44) | 10/25 (40) | |
| Switched B cells (mean%, range) | 1.74 (0–9) | 15.46 (0–59) | 11.80 (5–19) | 0.05 |
CID: combined immunodeficiency; CVID: common variable immunodeficiency; SID: secondary immunodeficiency; TI: thymoma and immunodeficiency; UnPAD: unclassified predominantly antibody deficiency; Ig: immunoglobulin; GLILD: granulomatous lymphocytic infiltration lung disease.